Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

The cancer-cell-killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor-mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC) who had not previously received chemotherapy.We randomly assigned patients to receive atezolizumab plus carboplatin plus...